Nasdaq

AbbVie's VRAYLAR® Gains Public Reimbursement In Alberta For Schizophrenia Treatment

(RTTNews) - AbbVie (ABBV) announced that Alberta has added VRAYLAR® - cariprazine to its Health Drug Formulary, expanding public coverage for adults living with schizophrenia. This milestone ensures ...
Seeking Alpha

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta

This listing is a new step towards more equitable access to mental illness medication in Canada. As up to 90% of Canadians with serious mental illness are unemployed 3, public plan coverage is ...
Nasdaq

AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions

Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions New discovery program builds upon nearly two decades of partnership between AbbVie and ...
BioWorld

Vraylar abattoir? Second MDD win for Intra-Cellular with Caplyta

Wall Street is mulling Intra-Cellular Therapeutics Inc.’s chances of replicating with Caplyta (lumateperone) the path followed by Abbvie Inc. with Vraylar (cariprazine) in major depressive disorder ...
Seeking Alpha

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario

VRAYLAR is an oral, once daily atypical antipsychotic approved as monotherapy for the treatment of schizophrenia in adults, as well as the acute management of manic, mixed, and depressive episodes ...